JAX strives to advance rare disease research and treatment options

For the past six years, the JAX Rare Disease Translational Center has worked with dozens of rare disease foundations to create custom mouse models that represent rare medical conditions, the majority of which present in young children.

In May 2022, JAX appointed Cathleen (Cat) Lutz, Ph.D., M.B.A. as Vice President of the Rare Disease Translational Center, marking an important step forward in its commitment to rare disease research. The expansion positions the Center to play an integral role throughout the entire rare disease odyssey, from diagnosis to research to drug development. The Center also collaborates closely with biotech and pharmaceutical companies to accelerate the path to drug discovery for these debilitating conditions. By taking a more holistic approach, the Center will make a significant impact on the experience of those living with rare diseases. Read more

Related Posts

Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research

The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...

22 August 2024

Bigelow lab receives $7 million for algae research, business development

Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...

21 August 2024

Should Maine create a public medical school? UMaine System will study the question

The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...

21 August 2024